The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)

Dipeptidyl peptidase-4 (DPP-4) inhibitors may have protective effects in the early stage of atherosclerosis in patients with type 2 diabetes, although similar effects in advanced atherosclerosis were not shown...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Original investigation Source Type: research

Related Links:

Source: BMJ Comments - Category: General Medicine Source Type: forums
Source: BMJ - Category: General Medicine Source Type: research
Dipeptidyl peptidase-4 inhibitor is an incretin-based agent used to treat type 2 diabetes mellitus, which has been available in the Taiwan market since 2009.1 Pancreatic cancer was the eighth leading cause of cancer death in Taiwan in 2017.2 At present, no definite evidence is available on the association between pancreatic cancer and dipeptidyl peptidase-4 inhibitors in Taiwan. To evaluate this issue, a population-based case-control study was conducted using the database of the Taiwan National Health Insurance Program with 23 million citizens living in the independent country of Taiwan.
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Tags: Letter to the Editor Source Type: research
Authors: Ku HC, Liang YJ Abstract INTRODUCTION: Diabetic foot ulcers are a serious complication of diabetes and are associated with pain, disability and poor quality of life. Incretin-based therapy is available for type-2 diabetes. Aside from glucose control, such treatment can impart numerous beneficial effects. Areas covered: This review summarizes the preclinical and clinical evidence supporting incretin-based treatment approaches for diabetic ulcers. Expert opinion: Incretin-based therapy may have a role in the treatment of diabetic foot ulcers; the benefits of such treatment arise from attenuation of inflammat...
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
AimsThe use of incretin ‐based therapy instead of or complementary to insulin therapy is an active area of research in hospitalized patients with type 2 diabetes (T2D). We determined glycaemic efficacy and safety of linagliptin compared to basal‐bolus insulin regimen in hospitalized surgical patients with T2D.Materials and MethodsThis prospective open ‐label multicenter study randomized T2D patients undergoing non‐cardiac surgery with admission blood glucose(BG) 7.8‐22.2 mmol/L treated with diet, oral agents or total insulin dose(TDD) ≤0.5 units/kg/day to linagliptin(n=128) daily or basal‐bolus(n=122) with g...
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Tags: ORIGINAL ARTICLE Source Type: research
This article has been written to answer frequent questions about metabolic surgery results and the mechanisms of action. For this purpose, a non-systematic search of different databases was carried out, identifying articles published in the last decade referring to the mechanisms of action of metabolic techniques. Understanding these mechanisms will help grasp why some surgeries are more effective than others and why the results can be so disparate among patients undergoing the same surgical approach.ResumenLa cirugía bariátrica y metabólica está desarrollando nuevos conceptos sobre la asimilaci...
Source: Cirugia Espanola - Category: Surgery Source Type: research
Background: Type 2 diabetes mellitus is a disease correlated with obesity. Obese patients has suppressed incretin effect and inbalance of glycemic homeostasis. Studies have shown improvement in DM2 after Roux-en-Y gastric bypass (RYGB). The mechanisms of glycemic control may be long-term and short-term. The mechanisms of early action are linked to caloric restriction, improvement of insulin resistance, pancreatic beta cell function and return of the incretin effect through the increase of GLP1 and GIP, but data are conflicting.
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Source Type: research
This article has been written to answer frequent questions about metabolic surgery results and the mechanisms of action. For this purpose, a non-systematic search of different databases was carried out, identifying articles published in the last decade referring to the mechanisms of action of metabolic techniques. Understanding these mechanisms will help grasp why some surgeries are more effective than others and why the results can be so disparate among patients undergoing the same surgical approach. PMID: 30337047 [PubMed - as supplied by publisher]
Source: Cirugia eEspanola - Category: Surgery Authors: Tags: Cir Esp Source Type: research
Incretin-based drugs are a relatively new class of medications for the treatment of type 2 diabetes, based upon the glucose-lowering actions of the gastrointestinal incretin hormones (e.g., the Glucagon-Like Peptide-1, GLP-1) [1]. They act either inhibiting the enzyme Dipeptidyl Peptidase-4 (DPP-4) that degrades the endogenous GLP-1 – as the DPP-4 inhibitors sitagliptin, saxagliptin, alogliptin – or mimicking the effects of GLP-1 – as the GLP-1 receptor agonists exenatide and liraglutide [2,3]. These drugs have been approved as an alternative or additional treatment in patients with inadequate diabetes co...
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
Purpose of review Cardiovascular outcome trials (CVOT) with glucagon-like peptide-1 receptor agonists (GLP-1 RA) have had variable results to date: with two CVOTs being positive and two concluding neutrality/safety results for primary cardiovascular outcome. Mechanistic insights delving into the pathophysiologic mechanisms that may link certain GLP-1 RA to cardioprotection may help define the application of this medication class in clinical practice based on the evidence of the CVOT data. We discuss the various mechanisms that have been postulated from animal and preclinical human studies to help explain the benefits obs...
Source: Current Opinion in Cardiology - Category: Cardiology Tags: Special Commentaries Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Fortamet | Heart | Incretin Therapy | Metformin | Study